


WHO grants 'emergency validation' to Pfizer-BioNTech vaccine

1 January 2021



Credit: Pixabay/CC0 Public Domain

The World Health Organization on Thursday granted emergency validation to the Pfizer-BioNTech vaccine, paving the way for countries worldwide to quickly approve its import and distribution.

Britain launched its inoculation drive with the US-German [vaccine](#) on December 8, with the United States, Canada and EU countries following suit.

WHO said the Pfizer/BioNTech vaccine was the first to receive its "emergency validation" since the novel [coronavirus](#) first broke out in China a year ago.

"This is a very positive step towards ensuring global access to COVID-19 vaccines," said Mariangela Simao, a top WHO official tasked with ensuring access to medicines.

"But I want to emphasise the need for an even greater global effort to achieve enough [vaccine](#)

[supply](#) to meet the needs of priority populations everywhere," she said in a statement.

WHO said its emergency use listing opens the way for regulators in different countries to approve the import and distribution of the vaccine.

It said it also enables UNICEF, which plays a key logistical role in distributing anti-COVID vaccines, and the Pan-American Health Organization to procure the vaccine for countries that need it.

WHO convened its own experts and those from around the world to review the data on the Pfizer/BioNTech vaccine's "safety, efficacy and quality," weighing the benefits against the risks.

"The review found that the vaccine met the must-have criteria for safety and efficacy set out by WHO, and that the benefits of using the vaccine to address COVID-19 offset potential risks," it said.

© 2021 AFP

APA citation: WHO grants 'emergency validation' to Pfizer-BioNTech vaccine (2021, January 1) retrieved 27 April 2021 from <https://medicalxpress.com/news/2021-01-grants-emergency-validation-pfizer-biontech-vaccine.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.